List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9309990/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet, The, 2020, 395, 1208-1216.	13.7	1,108
2	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	27.0	982
3	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	1.9	488
4	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	1.9	278
5	Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	210
6	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq0 0 0 rgE 2020, 21, 1331-1340.	T /Overloo 10.7	ck 10 Tf 50 5 197
7	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	1.9	190
8	Sepsis and â€~superbugs': should we favour the transperineal over the transrectal approach for prostate biopsy?. BJU International, 2014, 114, 384-388.	2.5	187
9	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications, 2017, 8, 13671.	12.8	182
10	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
11	Investigations with FDG-PET Scanning in Prostate Cancer Show Limited Value for Clinical Practice. Acta Oncológica, 2002, 41, 425-429.	1.8	115
12	Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis. European Urology, 2015, 67, 496-503.	1.9	112
13	Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis. Journal of Urology, 2019, 201, 715-720.	0.4	103
14	The Metaplastic Effects of Estrogen on Mouse Prostate Epithelium: Proliferation of Cells with Basal Cell Phenotype ¹ . Endocrinology, 2001, 142, 2443-2450.	2.8	92
15	Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer. Psycho-Oncology, 2017, 26, 1576-1585.	2.3	91
16	A preclinical xenograft model of prostate cancer using human tumors. Nature Protocols, 2013, 8, 836-848.	12.0	90
17	Laparoscopic and robotâ€assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review. BJU International, 2018, 121, 845-853.	2.5	88
18	Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. European Urology, 2017, 72, 492-495.	1.9	81

#	Article	IF	CITATIONS
19	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	1.9	80
20	Enduring epigenetic landmarks define the cancer microenvironment. Genome Research, 2018, 28, 625-638.	5.5	74
21	Detection and localisation of primary prostate cancer using ⁶⁸ gallium prostateâ€specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU International. 2020. 126. 83-90.	2.5	69
22	Semantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322.	3.8	65
23	The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. BJU International, 2013, 111, E158-66.	2.5	61
24	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
25	New Challenges in Psycho-Oncology Research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications. Psycho-Oncology, 2017, 26, 873-913.	2.3	55
26	Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. International Journal of Cancer, 2020, 146, 161-168.	5.1	54
27	ls Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. European Urology, 2021, 79, 413-418.	1.9	52
28	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51
29	A proâ€ŧumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, <scp>CXCL12</scp> and mast cell recruitment. Journal of Pathology, 2014, 234, 86-98.	4.5	47
30	Androgen deprivation therapy complications. Endocrine-Related Cancer, 2014, 21, T119-T129.	3.1	43
31	Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasoundâ€guided biopsy: the Victorian Transperineal Biopsy Collaboration experience. BJU International, 2015, 116, 568-576.	2.5	42
32	Holmium Laser Enucleation of the Prostate: Comparison of Immediate Postoperative Outcomes in Patients with and without Antithrombotic Therapy. Current Urology, 2013, 7, 28-33.	0.6	40
33	Effects of Testosterone Plus Medroxyprogesterone Acetate on Semen Quality, Reproductive Hormones, and Germ Cell Populations in Normal Young Men. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 546-556.	3.6	40
34	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrateâ€ŧolerant cells. BJU International, 2018, 121, 971-978.	2.5	39
35	Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. Psycho-Oncology, 2013, 22, 2169-2176.	2.3	36
36	Prostate cancer survivorship essentials framework: guidelines for practitioners. BJU International, 2021, 128, 18-29.	2.5	35

#	Article	IF	CITATIONS
37	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021, 12, 5049.	12.8	33
38	Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer. Prostate, 2015, 75, 1475-1483.	2.3	31
39	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. SLAS Discovery, 2021, 26, 1107-1124.	2.7	30
40	Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nature Reviews Urology, 2016, 13, 258-265.	3.8	28
41	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	1.9	28
42	Knowing what's growing: Why ductal and intraductal prostate cancer matter. Science Translational Medicine, 2020, 12, .	12.4	27
43	The Metaplastic Effects of Estrogen on Mouse Prostate Epithelium: Proliferation of Cells with Basal Cell Phenotype. Endocrinology, 2001, 142, 2443-2450.	2.8	27
44	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	5.4	24
45	A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients. Palliative and Supportive Care, 2020, 18, 130-140.	1.0	20
46	Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts. Oncotarget, 2016, 7, 47650-47662.	1.8	18
47	Development of Indicators to Assess Quality of Care for Prostate Cancer. European Urology Focus, 2018, 4, 57-63.	3.1	17
48	Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer. Clinical Epigenetics, 2020, 12, 48.	4.1	17
49	Impact of branding on public awareness of healthcareâ€related governing bodies: a pilot study of the Urological Society of Australia and New Zealand brand. BJU International, 2016, 118, 23-29.	2.5	16
50	Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia. BMC Urology, 2016, 16, 54.	1.4	16
51	Work after prostate cancer: a systematic review. Journal of Cancer Survivorship, 2019, 13, 282-291.	2.9	15
52	Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. European Urology Oncology, 2022, 5, 314-320.	5.4	15
53	Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial. BMJ Open, 2018, 8, e022331.	1.9	14
54	Contemporary consumer perspectives on prostate cancer survivorship: Fifty voices. Psycho-Oncology, 2020, 29, 557-563.	2.3	13

#	Article	IF	CITATIONS
55	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. European Journal of Cancer, 2021, 148, 440-450.	2.8	13
56	Establishing a cryopreservation protocol for patientâ€derived xenografts of prostate cancer. Prostate, 2019, 79, 1326-1337.	2.3	12
57	⁶⁸ Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer. Journal of Urology, 2022, 207, 341-349.	0.4	12
58	Patterns of care for prostate cancer treatment and improving outcomes – are national registries the answer?. BJU International, 2021, 128 Suppl 1, 6-8.	2.5	11
59	High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma. BJU International, 2019, 124, 907-909.	2.5	10
60	Prostate cancer screening in Primary Health Care: the current state of affairs. SpringerPlus, 2015, 4, 78.	1.2	9
61	Radical prostatectomy: what do the patients really think of surgery?. Medical Journal of Australia, 1998, 168, 477-478.	1.7	7
62	Longâ€ŧerm experience of residual symptoms following treatment for localized prostate cancer: An Australian sample. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 199-206.	1.1	7
63	National nephrectomy registries: Reviewing the need for population-based data. Korean Journal of Urology, 2015, 56, 607.	1.2	7
64	Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate. Scientific Reports, 2017, 7, 10150.	3.3	7
65	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 929.e1-929.e10.	1.6	7
66	Can Exercise Adaptations Be Maintained in Men with Prostate Cancer Following Supervised Programmes? Implications to the COVID-19 Landscape of Urology and Clinical Exercise. European Urology Open Science, 2020, 21, 47-50.	0.4	7
67	How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. Journal of Urology, 2022, 207, 1048-1056.	0.4	7
68	Nephron-sparing surgery for small incidental renal cell carcinoma. ANZ Journal of Surgery, 2001, 71, 349-353.	0.7	6
69	An integrated multicomponent care model for men affected by prostate cancer: A feasibility study of TrueNTH Australia. Psycho-Oncology, 2021, 30, 1544-1554.	2.3	6
70	The role of open radical nephrectomy in contemporary management of renal cell carcinoma. Translational Andrology and Urology, 2020, 9, 3123-3139.	1.4	6
71	MANAGEMENT OF SUPERFICIAL BLADDER CANCER IN VICTORIA: 1990 AND 1995. ANZ Journal of Surgery, 2005, 75, 270-274.	0.7	5
72	Early Androgen Deprivation Therapy Improves Survival, But How Do We Determine in Whom?. European Urology, 2018, 73, 519-520.	1.9	5

#	Article	IF	CITATIONS
73	Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. Scientific Reports, 2021, 11, 6352.	3.3	5
74	â€~Painâ€free TRUS B': a phase 3 doubleâ€blind placeboâ€controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonographyâ€guided prostate biopsy (ANZUP 1501). BJU International, 2022, 129, 591-600.	ו 2.5	5
75	PSA testing for men at average risk of prostate cancer. Public Health Research and Practice, 2017, 27, .	1.5	5
76	Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and metaâ€analysis BJU International, 2021, , .	2.5	5
77	Reliability of negative multiparametric <scp>MRI</scp> of the prostate: can we avoid the biopsy? Not yet!. BJU International, 2017, 119, E9-E10.	2.5	4
78	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
79	Quality of life considerations in the treatment of metastatic hormone-sensitive prostate cancer. Lancet Oncology, The, 2019, 20, 1469-1471.	10.7	3
80	Predictors of erectile dysfunction after transperineal template prostate biopsy. Investigative and Clinical Urology, 2021, 62, 159.	2.0	3
81	Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?. Investigative and Clinical Urology, 2021, 62, 650.	2.0	3
82	Diagnosing prostate cancer - what GPs need to know. Australian Family Physician, 2007, 36, 345-7.	0.5	3
83	Monitoring cardiovascular health in men with prostate cancer treated with androgen deprivation therapy. International Journal of Urological Nursing, 2012, 6, 35-41.	0.2	2
84	Avoiding biopsy in men with <scp>Plâ€RADS</scp> scores 1 and 2 on multiparametric <scp>MRI</scp> of the prostate, ready for prime time?. BJU International, 2019, 124, 715-716.	2.5	2
85	Care beyond prostate cancer—improving patient outcomes. Nature Reviews Urology, 2014, 11, 669-671.	3.8	1
86	68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. World Journal of Urology, 2021, 39, 4117-4125.	2.2	1
87	Selfâ€reported lack of energy or feeling depressed 12Âmonths after treatment in men diagnosed with prostate cancer within a populationâ€based registry. Psycho-Oncology, 2021, , .	2.3	1
88	Re: 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2019, 76, 405.	1.9	0
89	Editorial Comment. Journal of Urology, 2019, 202, 1247-1247.	0.4	0
90	PSA testing. Australian Family Physician, 2003, 32, 396.	0.5	0